thassodotcom
Posted in Allelic Variant, Genetic Background, Genetic Predisposition, Genetic Susceptibility, Pharmacogenetics, Regulatory Announcement, Thasso Post, Theragenomic Medicine
No Comments ↓
April 07, 2019 – Consumers are increasingly embracing genetic testing to better understand their individual risk for developing diseases. With this rise in popularity and availability, we’re also seeing significant activity in the field of pharmacogenetics, which is the process of understanding what, if any, role genetics plays in a patient’s reaction to particular drugs,
…
thassodotcom
Posted in Drug/Drug Interaction, Genetic Background, New Research, Pharmacogenetics, Thasso Post, Theragenomic Medicine
No Comments ↓
January 26, 2019 – Pharmacogenomic approaches are increasingly revealing newly identified genes and genetic variants that are at the base of remarkable inter-individual pharmacokinetic and pharmacodynamic variation of novel direct oral anticoagulants (DOAC).
…
thassodotcom
Posted in Genetic Background, Genetic Predisposition, Personalized Medicine, Pharmacogenetics, Regulatory Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine
No Comments ↓
Thus, FDA permits marketing, with special controls,
…
thassodotcom
Posted in Companion Test, Genetic Background, Genetic Predisposition, Genetic Susceptibility, Personalized Medicine, Pharmacogenetics, Targeted Therapy, Thasso Post, Theragenomic Medicine
No Comments ↓
June 16, 2017 – Patient education in pharmacogenetics, the central component of theragenomic and personalized medicine and individualized drug safety is an important issue. Not only needs the individual patient to understand what pharmacogenetics, or more precisely, pharmacogenetic testing can do for him in the process of
selection of the “right”
…
thassodotcom
Posted in Genetic Background, In The Press, New Drug Approval, Personalized Medicine, Pharmacogenetics, Rare Diseases, Regulatory Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine
No Comments ↓
September 19, 2016 – This post presents below a virtually unedited announcement by the American Food & Drug Administration (FDA) concerning Duchenne Muscular Dystrophy (DMD) therapy  option which gives much hope for at least some of the affected patients.
…
Sacco K, Grech G
Posted in Personalized Medicine, Pharmacogenetics, PubMed Entry, Thasso Post, Theragenomic Medicine
No Comments ↓
Sacco K, Grech G
EPMA J 2015;6(1):15
PMID: 26203310
Abstract
Breast cancer is a heterogeneous disease that necessitates proper patient classification to direct surgery, pharmacotherapy, and radiotherapy. Despite patients within the same subgroup receiving similar pharmacotherapy, substantial variation in clinical outcomes is observed.
…
thassodotcom
Posted in Allelic Variant, Companion Test, Diagnostic, Genetic Background, Genetic Predisposition, Genetic Susceptibility, On The Horizon, Personalized Medicine, Pharmacogenetics, Regulatory Announcement, Targeted Therapy, Thasso Post, Theragenomic Medicine
No Comments ↓
…
thassodotcom
Posted in Allelische Variante, Genetic Predisposition, Personalized Medicine, Pharmacogenetics, Regulatory Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine, Uncategorized
No Comments ↓
February 07, 2016 – The European Commission has approved once-daily Osimertinib (Tagrissa) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) that is positive for the epidermal growth-factor receptor (EGFR) T790M mutation. This follows a positive review in December 2015.
…
thassodotcom
Posted in New Drug Approval, Personalized Medicine, Pharmacogenetics, Thasso Post, Theragenomic Medicine
No Comments ↓
…
Optional: Social Subscribe/Login
thasso: recent comments